NVS logo

NVS
Novartis AG

6,792
Mkt Cap
$251.16B
Volume
2.06M
52W High
$134.24
52W Low
$96.06
PE Ratio
17.92
NVS Fundamentals
Price
$132.36
Prev Close
$131.19
Open
$132.46
50D MA
$129.41
Beta
0.26
Avg. Volume
1.64M
EPS (Annual)
$5.91
P/B
5.73
Rev/Employee
$662,711.55
Loading...
Loading...
News
all
press releases
Dearborn Partners LLC Sells 26,963 Shares of Novartis AG $NVS
Dearborn Partners LLC cut its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 43.4% in the second quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Novartis AG (NYSE:NVS) Receives Average Recommendation of "Hold" from Analysts
Novartis AG (NYSE:NVS - Get Free Report) has been assigned an average rating of "Hold" from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. Three research analysts...
MarketBeat·20h ago
News Placeholder
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.read more...
Benzinga·3d ago
News Placeholder
First Trust Advisors LP Trims Stock Holdings in Novartis AG $NVS
First Trust Advisors LP lessened its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·3d ago
News Placeholder
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS
Baird Financial Group Inc. lessened its stake in Novartis AG (NYSE:NVS - Free Report) by 18.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 69,062 shares of...
MarketBeat·3d ago
News Placeholder
JPMorgan Chase & Co. Upgrades Novartis (NYSE:NVS) to "Overweight"
JPMorgan Chase & Co. upgraded shares of Novartis from a "neutral" rating to an "overweight" rating in a report on Monday...
MarketBeat·4d ago
News Placeholder
Price Over Earnings Overview: Novartis
read more...
Benzinga·6d ago
News Placeholder
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Zacks·7d ago
News Placeholder
Dodge & Cox Cuts Stock Position in Novartis AG $NVS
Dodge & Cox trimmed its position in shares of Novartis AG (NYSE:NVS - Free Report) by 9.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·7d ago
News Placeholder
CW Advisors LLC Buys 26,009 Shares of Novartis AG $NVS
CW Advisors LLC boosted its position in Novartis AG (NYSE:NVS - Free Report) by 52.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat·7d ago

Latest NVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.